2003
DOI: 10.1021/jm030765s
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis and Structure−Activity Relationship of a New Series of COX-2 Selective Inhibitors:  1,5-Diarylimidazoles

Abstract: The synthesis and the pharmacological activity of a series of 1,5-diarylimidazoles developed as potent and selective cyclooxygenase-2 (COX-2) inhibitors are described. The new compounds were evaluated both in vitro (COX-1 and COX-2 inhibition in human whole blood) and in vivo (carrageenan-induced paw edema, air-pouch, and hyperalgesia tests). Modification of all the positions of two regioisomeric imidazole cores led to the identification of 4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl]benzenesulfonami… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

2
58
0

Year Published

2005
2005
2022
2022

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 128 publications
(60 citation statements)
references
References 38 publications
2
58
0
Order By: Relevance
“…[22,23] To test this hypothesis, we reacted 10i with 1.05 equiv. of Nbromosuccinimide (NBS) in acetonitrile at room temperature and obtained a mixture of 4-bromo derivative 11g and a small amount (about 3-4 %) of 2-bromo derivative 18.…”
Section: Synthesis Of 5-aryl-4-bromo-1-methyl-1h-imidazolesmentioning
confidence: 99%
“…[22,23] To test this hypothesis, we reacted 10i with 1.05 equiv. of Nbromosuccinimide (NBS) in acetonitrile at room temperature and obtained a mixture of 4-bromo derivative 11g and a small amount (about 3-4 %) of 2-bromo derivative 18.…”
Section: Synthesis Of 5-aryl-4-bromo-1-methyl-1h-imidazolesmentioning
confidence: 99%
“…Recently, it was discovered that COX exist in two isoforms, COX-1 and COX-2, which are regulated differently [6,7]. COX-1 provides cytoprotection in the gastrointestinal tract whereas inducible COX-2 mediates inflammation [8,9]. Thus the discovery of COX-2 provided the rationale for the development of drugs devoid of GI disorders while retaining clinical efficacy as anti-inflammatory agents.…”
Section: Introductionmentioning
confidence: 99%
“…Recently, it was discovered that COX exists in two isoforms, COX-1 and COX-2, which are regulated differently [7,8]. COX-1 provides cytoprotection in the gastrointestinal (GI) tract whereas inducible COX-2 mediates inflammation [9,10]. Since most of the NSAIDs in the market show greater selectivity for COX-1 than COX-2 [11], chronic use of NSAIDs may elicit appreciable GI irritation, bleeding and ulceration [12].…”
mentioning
confidence: 99%